Wall Street is opening its coffers again for risky drug developers. Many small biotechnology companies have struggled to raise money in recent years. Public markets were all but shut. Initial public ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min While many have been hoping for ...
Spécialiste du conseil en développement pharmaceutique, la biotech héraultaise Inits se dote de capacités productives en réceptionnant son usine, où elle a injecté 28 millions d’euros. Elle prévoit 20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results